Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Patent
1998-03-26
1999-10-19
Degen, Nancy
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
435 911, 435325, 435366, 435375, 536 231, 536 2431, 536 245, C12Q 168, C12N 1585, C07H 2104
Patent
active
059687487
ABSTRACT:
Compounds, compositions and methods are provided for inhibiting the expression of human HER-2 (also known as c-neu, ErbB-2 and HER-2
eu). The compositions comprise antisense oligonucleoptides targeted to nucleic acids encoding HER-2. Methods of using these oligonucleotides for inhibition of HER-2 expression and for treatment of diseases such as cancers associated with overexpression of HER-2 are provided. Methods of inhibiting other growth factor receptors using antisense oligonucleotides targeted to nucleic acids encoding HER-2 are also provided.
REFERENCES:
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5138045 (1992-08-01), Cook et al.
patent: 5218105 (1993-06-01), Cook et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5539082 (1996-07-01), Nielsen et al.
Berge et al., "Pharmaceutical Salts", J. Pharma. Sci., 1977, 66, 1-19.
Bertram et al., "Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tryosine kinase consensus phosphorothioate antisense oligonucleotides", Biochem. Biophys. Res. Commun., 1994, 200(1), 661-667.
Brysch et al., "Inhibition of p185.sup.c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation", Cancer Gene Ther., 1994, 1(2), 99-105.
Casalini et al., "Inhibition of Tumorigenicity in Lung Adenocarcinoma Cells by c-erbB-2 Antisense Expression", Int. J. Cancer, 1997, 72, 631-636.
Chang et al., "The tumor suppression activity of E1A in HER-s
eu-overexpression breast cancer", Oncogene, 1977, 14, 561-568.
Chiang et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms", J. Biol. Chem., 1991, 266, 18162-18171.
Chonn et al., "Recent advances in liposomal drug-delivery systems", Curr. Op. Biotech., 1995, 6, 698-708.
Cohen et al., "The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells", J. Biol. Chem., 1996, 271(48), 30897-30903.
Colomer et al., "erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification", Br. J. Cancer, 1994, 70, 819-825.
Crooke et al., "Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in mice", J. Pharmacol. Exp. Therapeutics, 1996, 277, 923-937.
De Mesmaeker et al., "Antisense Oligonucleotides", Acc. Chem. Res., 1995, 28, 366-374.
Ebbinghaus et al., "Triplex Formation Inhibits HER-2
eu Transcription in Vitro", J. Clin. Invest., 1993, 92, 2433-2439.
Gebeyehu et al., "Novel bitinylated nucleotide--analogs for labeling and colorimetric detection of DNA", Nuc. Acids Res., 1987, 15, 4513-4534.
Juhl et al., "HER-2
eu is Rate-limiting for Ovarian Cancer Growth", J. Biol. Chem., 1997, 272(47), 29482-29486.
Kabanov et al., "A new class of antivirals: antisense olgonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells", FEBS Letts., 1990, 259, 327-330.
Kawasaki et al., "Uniformly Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets", J. Med. Chem., 1993, 831-841.
Kornberg, DNA Replication, W.H. Freeman & Co., San Francisco, 1974, 75-77.
Korutla et al., "Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin", Carcinogenesis, 1995, 16(8), 1741-1745.
Kumar et al., "Interferon .alpha. induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: Role in growth regulation", Proc. Natl. Acad. Sci. USA, 1992, 89, 6599-6603.
Lee et al., Crit. Rev. Therp. Drug Carrier Sys., 1991, 8, 91-192.
Letsinger et al., "Cholesterol-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture", Proc. Natl. Acad. Sci., 1989, 86, 6553-6556.
Liu et al., "Inhibition of erbB-2-Positive Breast Cancer Cell Growth by erbB-2 Antisense Oligonucleotides", Antisense Nucl. Acid Drug Devel., 1996, 6, 9-16.
Manoharan et al., "Cholic Acid-Oligonucliotide Conjugates for Antisense Applications", Bioorganic Med. Chem. Letts., 1994, 4, 1053-1060.
Manoharan et al., "Chemical Modifications to Improve Uptake and Bioavailability of Antisense Oligonucleotides", Ann. NY Acad. Sciences, 1992, 660, 306-309.
Manoharan et al., "Lipidic Nucleic Acids", Tetrahedron Letts., 1995, 36, 3651-3654.
Manoharan et al., "Oligonucleotide Conjugates: Alteration of the Pharmacokinetic Properties of Antisense Agents", Nucleosides and Nucleotides, 1995, 14, 969-973.
Manoharan et al., "Introduction of a Lipophilic Thioether Tether in the Minor Groove of Nucleic Acids for Antisense Applications", Bioorg. Med. Chem. Letts., 1993, 3, 2765-2770.
Martin et al., "Ein neuer Zugang zu 2'-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide", Helvetica Chemica Acta, 1995, 78, 486-504.
Mishra et al., "Improved leishmanicidal effect of phosphorotioate antisense oligonucleotides by LDL-medicated delivery", Biochim. Et Biophysica, 1995, 1264,229-237.
Muranishi, "Absorption, Enhancers", Crit. Rev. Ther. Drug Carrier Systems, 1990, 7, 1-33.
Nielsen et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide", Science, 1991, 254, 1497-1500.
Oberhauser et al., "Effective incorporation of 2'-O-methyl-oligonucleotides into liposomes and enhanced cell association through modification with thiocholesterol", Nucl. Acids Res., 1992, 20, 533-538.
Pegues et al., "Inducible antisense inhibition of erbB-2 expression reduces anchorage independent growth of ovarian carcinoma cells", Cancer Lett., 1997, 117, 73-79.
Porumb et al., "Temporary ex Vivo Inhibition of the Expression of the Human Oncogene HER2 (NEU) by a Triple Helix-forming Oligonucleotide", Cancer Res., 1996, 56, 515-522.
Saison-Behmoaras et al., "Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation", EMBO J., 1991, 10, 1111-1118.
Sanghvi et al., "Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines", Nucl. Acids Res., 1993, 21, 3197-3203.
Shea et al., "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucletide conjugates", Nucl. Acids Res., 1990, 18, 3777-3783.
Svinarchuk et al., "Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to lipophilic groups", Biochimie, 1993, 79, 49-54.
Tan et al., "Overexpression of the c-erbB-2 Gene Enhanced Intrinsic Metastasis Potential in Human Breast Cancer Cells without Increasing Their Transformation Abilities", Cancer Res., 1997, 57, 1199-1205.
Ueno et al., "Chemosensitization of HER-2
eu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A", Oncogene, 1997, 15, 953.
Valone et al., "Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpreses HER-2
eu", J. Hematotherapy, 1995, 4, 471-475.
Vaughn et al., "Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphoroditheoate antisense oligonucleotides", Nucl. Acids Res., 1996, 24(22), 4558-4564.
Wiechen et al., "c-erbB-2 Anti-Sense Phosphorothioate Oligodeoxynucleotides Inhibit Growth and Serum-Induced Cell Spreading of P185.sup.c-34bB-2 -Overexpressing Carcinoma Cells", Int. J. Cancer, 1995, 63, 604-608.
Witters et al., "Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody", Breast Cancer Res. Treat., 1997, 42, 1-5.
Yamamoto et al., "Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor", Nature, 1986, 319, 230-234.
Zhang et al., "Sensitization of HE
Bennett C. Frank
Lipton Allan
Witters Lois M.
Degen Nancy
ISIS Pharmaceuticals Inc.
The Penn State Research Foundation
Wang Andrew
LandOfFree
Antisense oligonucleotide modulation of human HER-2 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotide modulation of human HER-2 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotide modulation of human HER-2 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2054455